



doc

1853
RECEIVED
MAR 13 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 38005-0158

In re patent application of
STILZ, Hans Ulrich *et al.*

Confirmation No.: 3219

Application No.: 09/995,631

Group Art Unit: 1653

Filed: November 29, 2001

Examiner: David Lukton

For: NOVEL HETEROCYCLES AS INHIBITORS OF LEUCOCYTE ADHESION
AND AS VLA-4 ANTAGONISTS

AMENDMENT IN RESPONSE TO NOTICE
UNDER 37 CFR §§ 1.821 – 1.825

Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

RECEIVED
MAR 13 2002
TECH CENTER 1600/2900

Sir:

In response to the Notice to Comply with Requirements for Applications containing Sequence Disclosures mailed February 19, 2002, please amend the application as follows:

IN THE SPECIFICATION:

Page 1, paragraph 2, line 19: Please amend as follows:

B1 The integrins are a group of adhesion receptors which play an important part in cell-cell-binding and cell-extracellular matrix-binding processes. They have an $\alpha\beta$ -heterodimeric structure and exhibit a wide cellular distribution and a high extent of evolutive conservation. The integrins include, for example, the fibrinogen receptor on platelets, which interacts especially with the RGD sequence of fibrinogen, or the vitronectin receptor on osteoclasts, which interacts especially with the RGD sequence of vitronectin or of osteopontin. The integrins are divided into three major groups, the $\beta 2$ subfamily with the representatives LFA-1, Mac-1 and p150/95, which are responsible in particular for cell-cell interactions of the immune system, and the subfamilies $\beta 1$ and $\beta 3$, whose representatives mainly mediate cell adhesion to components of the extracellular matrix (Ruoslahti, Annu. Rev. Biochem. 1988, 57, 375). The integrins of the $\beta 1$ subfamily, also called VLA proteins (very late